Transgene to Present its Viral Vector Expertise at the Society for Immunotherapy of Cancer Conference

information fournie par Boursorama •02/10/2018 à 07:30

Transgene to Present its Viral Vector Expertise at the Society for Immunotherapy of Cancer Conference


Strasbourg, France – October 2, 2018, 7:30 am CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, will be presenting three posters highlighting the Company’s world-leading viral vector expertise and their potential to transform the fight against cancer at the annual meeting of the Society for Immunotherapy of Cancer (SITC) to be held November 7-11 in Washington DC (USA).

They will cover:
- Invir.IO (TM): a new generation of multifunctional oncolytic viruses;
- myvac (TM): an individualized immunotherapy based on a viral vector (MVA);
- a next generation viral vector for cancer immunotherapy (PCPV).
.../...